D'Huyvetter M, De Vos J, Caveliers V, Vaneycken I, et al. Phase I trial of (131)I-GMIB-Anti-HER2-VHH1, a new promising candidate for
HER2-targeted radionuclide therapy in breast cancer patients. J Nucl Med 2020 Dec 4. pii: jnumed.120.255679. doi: 10.2967/jnumed.120.255679.
PMID: 33277400